Sun Pharmaceutical Industries is currently trading at Rs. 817.95, up by 15.20 points or 1.89% from its previous closing of Rs. 802.75 on the BSE.
The scrip opened at Rs. 824.60 and has touched a high and low of Rs. 827.40 and Rs. 813.90 respectively. So far 112029 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1010.10 on 25-May-2015 and a 52 week low of Rs. 706.40 on 24-Nov-2015.
Last one week high and low of the scrip stood at Rs. 827.40 and Rs. 780.55 respectively. The current market cap of the company is Rs. 196643.83 crore.
The promoters holding in the company stood at 54.97%, while Institutions and Non-Institutions held 35.37% and 9.65% respectively.
India’s largest pharmaceutical firm, Sun Pharmaceutical is reportedly scouting for a partner to market 14 brands it acquired from Novartis in Japan. In April, a wholly-owned subsidiary of the company, acquired 14 established prescription brands from Novartis AG and Novartis Pharma AG in Japan, for $293 million.
The acquired brands will be marketed by a local marketing partner under the Sun label. The local marketing partner will also be responsible for distribution of the brands.
Sun Pharmaceutical is the world’s fifth largest specialty generic pharmaceutical company and India’s top pharmaceutical company. Its global presence is supported by 49 manufacturing facilities spread across 6 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1672.45 |
| Dr. Reddys Lab | 1223.65 |
| Cipla | 1230.25 |
| Zydus Lifesciences | 929.45 |
| Lupin | 2335.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: